Peer-influenced content. Sources you trust. No registration required. This is HCN.

ASH Clinical NewsUniversal CAR-T Platform Shows Promising Efficacy in Relapsed/Refractory AML

Published in Blood, this article presents initial findings from a proof-of-concept study led by Martin Wermke, MD, from the Technical University of Dresden in Germany. The UniCAR platform uses targeting molecule TM123 and a single-chain variable fragment that is directed against the CD123 antigen, offering a potential new treatment option for patients with relapsed/refractory acute myeloid leukemia (AML).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form